Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
236 Leser
Artikel bewerten:
(1)

Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io

- Dante Genomics uses the 1health.io platform to accelerate their go to market strategy and expand availability in all 50 states using the 1health online prescription services -

NEW YORK, Dec. 07, 2022Inc., a global leader in genomics and precision medicine, to help launch their whole genome sequencing test to their customers in the United States with online prescription services.

Dante Genomics is a global genomic information company that delivers clear, understandable medical reports to its customers based on whole genome sequencing. Once a person has sequenced their whole genome through Dante, they will have access to more than 90 clinical and wellness reports. These reports are generated at the click of a button within minutes with no need to re-test. Genetic counseling will also be made available to these customers. The idea is to integrate fast, accurate genomic information into healthcare to deliver more personalized medicine when you need it.

Dante Genomics is streamlining complex prescription workflows by integrating with the 1health platform which provides access to a network of independent physicians for users to obtain a prescription to order their test by answering a few questions at order entry and upload clinical records if needed to receive approval and obtain a prescription. Now, using 1health's online portal, consumers located anywhere across the United States can get a prescription upon approval to order their whole genome sequencing test, which provides them with the health data they need to understand their health and make informed and proactive decisions about their health whether preventive or exercising symptoms.

"Personalized medicine needs personalized data, and the whole genome is the most personalized data available to an individual to inform better healthcare decisions," said Andrea Riposati, CEO of Dante Genomics. "We like to say, 'sequence your data once, query it for a lifetime.' Now, in collaboration with 1health, we will be able to bring doctor-ordered whole genome sequencing to our customers in the U.S. with understandable, clinical reports available at your fingertips within minutes."

"1health mission is to make advanced diagnostic testing more accessible and affordable in healthcare," states Mehdi Maghsoodnia, Chief Executive Officer of 1health. "Having Dante Genomics on the 1health platform provides clinicians with some of the most advanced genomic testing to enable personalized precision care for their patients."

About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company's assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

About 1health.io
1health is driving healthcare innovation by empowering our laboratory partners to make modern diagnostic testing more accessible, affordable and simple in the healthcare industry. 1health provides laboratories with a modern, secure and easy to use software platform that makes it easy to launch new test products, onboard new clinical customers and compete in the growing at home and online commerce markets. The result is stronger, more-trusted relationships between laboratories and their customers, better healthcare outcomes for consumers, and ultimately more lives saved.

Contact:

Dante Genomics
Laura D'Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com

1health Media
Yasmin Hariri
Head of Marketing
yhariri@1health.io
www.1health.io


© 2022 GlobeNewswire (Europe)
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.